Trial Profile
Efficacy and safety of adjuvant trastuzumab in unselected HER2-positive breast cancer.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Oct 2014
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Antineoplastics
- Indications Early breast cancer; HER2 positive breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms INT-HER
- 15 Oct 2014 New trial record